Form 4: Soligenix CFO Acquires 20,000 Shares Through Stock Option Grant

Soligenix's Chief Financial Officer, Jonathan L. Guarino, acquired 20,000 shares through a stock option grant on December 12, 2024.

Summary

• Jonathan L. Guarino, the Chief Financial Officer of Soligenix, Inc., was granted a stock option to purchase 20,000 shares of common stock.
• The option was granted on December 12, 2024, with an exercise price of $3.31 per share.
• 25% of the option shares vested immediately, and the remaining 75% will vest in 12 equal installments every three months starting from December 12, 2024.
• The options expire on December 11, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The stock option grant aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of 25% immediately and the remaining 75% over 3 years is a typical vesting schedule for stock options.
• The exercise price of $3.31 is a common practice for stock options.

Stakeholder Impact

• The stock option grant may have a positive impact on shareholder confidence by aligning management's interests with those of the shareholders.

Key Dates

Keywords

stock options, insider trading, executive compensation, Soligenix, SNGX, Jonathan L. Guarino, CFO